To the Editor,
I read the recent publication on cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism with a great interest [1] . Aktürk et al. concluded that, "these data suggest that CTLA-4 A49G polymorphism does not contribute to the pathogenesis of lymphoproliferative diseases itself, nor does it increase the risk of autoimmune complications in patients with lymphoproliferative disease [1] ." Aktürk et al. tried to determine allele frequencies and genotype distributions for some autoimmune blood diseases. There are some problems with their conclusion. First, the study included only a few patients and no controls. Second, not all autoimmune blood diseases were analyzed; therefore, they cannot conclude that their finding supports or refutes the contribution of the studied polymorphism to the pathogenesis or risk of disease. Third, when investigating a single polymorphism the possibility of other polymorphisms that were not investigated, must be considered.
